GSK is currently conducting a phase III clinical study to evaluate the efficacy of its melanoma antigen epitope-3 (MAGE-A3) antigen-specific cancer immunotherapy (ASCI) in subjects with non-small cell lung cancer (NSCLC) [180]. The gene discussed is MAGEA3; the disease is non-small cell lung carcinoma.